Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial
Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine (MCV4) developed by Tianjin Cansino Biotechnology has been approved for ...
2016-02-15 READ MORE
Manufacturing Facility Ground Breaking and Contract-signing Ceremony for Third Round of Financing
October 30, 2015, Tianjin CanSino Biotechnology Inc. (CanSino) celebrated the ground breaking of its vaccine manufacturing facilities well as the contract ...
2015-10-31 READ MORE
CanSino Biotechnology Successfully Passed EU GMP Audit
On February 3-4, 2015, a team led by the Qualified Person (QP) of an EU pharmaceutical enterprise conducted a two-day GMP audit of CanSino..
2015-03-27 READ MORE
China’s First Ebola Vaccine Approved For Clinical Trials
The Chinese Academy of Military Medical Sciences (AMMS) announced today that an Ebola vaccine (jointly developed by its Bioengineering Institute and ..
2014-12-19 READ MORE
CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
CanSinotech submitted Clinical Trial Application (CTA) of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to China Food and Drug Administration.
2014-11-25 READ MORE
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2